STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

YMAB Y-MABS THERAPEUTICS INCORPORATED StockScouter® Report

3

StockScouter® Score

Y-MABS THERAPEUTICS INCORPORATED, a small cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with slightly higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Two or more executives, directors or major shareholders sold a small number of shares recently. Negative
  • Shares are being sold by financial institutions. Slightly negative for a small company like YMAB

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 80% done.
Progress: 40% done.
Low
High

Core Model Grades

A
D
F
B

Previous Ratings

1
4
2